Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 67

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 67
---
 remuneration committee works annually with our independent compensation consultant to review and amend the list of our peer group companies to be used in connection with assessing compensation practices and pay levels. The remuneration committee believes that the peer and market data provided by our independent compensation consultant is helpful in determining market-competitive compensation for our executives but does not tie any pay elements directly to specific benchmarks. Instead, the remuneration committee considers peer data as part of a market-check analysis that is used in conjunction with its assessments of numerous other factors, as noted under “Factors Used in Determining Executive Compensation” below. Fiscal Year 2024 Peer Group In October 2023, with recommendations from Aon, the remuneration committee determined the group of companies that would be appropriate peers for fiscal year 2024 compensation decisions, based on the following criteria:

| • | Stock Exchange: We focused on companies that are publicly traded on either the Nasdaq Stock Market, New York Stock Exchange or London Stock Exchange; |

| • | Sector & Geography: We focused on biotechnology or pharmaceuticals companies that are headquartered in the United States or United Kingdom; |

| • | Employee Size: We focused on companies with a headcount ranging from 1/3 to three times our then-current headcount (between 125 to 1,225 full-time employees); |

| • | Market Capitalization: We focused on companies with a market capitalization representing roughly 1/3rdto three times our then-current market capitalization (between $900 million to $7.8 billion); and |

| • | Revenue: We focused on companies with annual revenue below $690 million (compared to our approximately $225 million in then-projected revenue as a rapidly growing, newer commercial company). |

The peer group of companies that the remuneration committee referenced for the purpose of informing executive compensation decisions for fiscal year 2024 is listed below:

| Amicus Therapeutics (FOLD)       |     | Deciphera Pharmaceuticals (DCPH) |     | Replimune Group (REPL)      |
| Apellis Pharmaceuticals (APLS)   |     | Galapagos (GLPG)                 |     | Revolution Medicines (RVMD) |
| Arcus Biosciences (RCUS)         |     | IDEAYA Biosciences (IDYA)        |     | TG Therapeutics (TGTX)      |
| Arrowhead Pharmaceuticals (ARWR) |     | Immatics (IMTX)                  |     |